行情

CCXI

CCXI

ChemoCentryx
NASDAQ

实时行情|Nasdaq Last Sale

55.35
+1.05
+1.93%
盘后: 55.35 0 0.00% 16:00 08/05 EDT
开盘
54.25
昨收
54.30
最高
56.16
最低
54.25
成交量
50.64万
成交额
--
52周最高
65.43
52周最低
6.16
市值
37.08亿
市盈率(TTM)
-50.3548
分时
5日
1月
3月
1年
5年

分析师评级

8位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测CCXI价格均价为73.00,最高价位95.00,最低价为61.00。

EPS

CCXI 新闻

更多
ChemoCentryx to Present at Two Upcoming Investor Conferences
MOUNTAIN VIEW, Calif., Aug. 04, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences in August: BTIG Virtual Biotech
GlobeNewswire · 1天前
ChemoCentryx to Hold Second Quarter 2020 Financial Results Conference Call on Monday, August 10, 2020
MOUNTAIN VIEW, Calif., Aug. 03, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's second quarter 2020 financial results will be released after market close on Monday, August 10, 2020. ChemoCentryx executive managem
GlobeNewswire · 2天前
Insiders Roundup: Mastercard, ChemoCentryx
GuruFocus.com · 07/17 16:02
Did Hedge Funds Make The Right Call On ChemoCentryx Inc (CCXI) ?
The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F filings show the funds' and investors' portfolio positions as of
Insider Monkey · 07/13 14:43
Insiders Roundup: Mastercard, Eli Lilly
GuruFocus.com · 07/10 16:11
ChemoCentryx Submits New Drug Application to the U.S. FDA for Avacopan in ANCA-Associated Vasculitis
GlobeNewswire · 07/09 13:30
ChemoCentryx files U.S. avacopan application for blood vessel inflammation
Seeking Alpha - Article · 07/09 12:45
ChemoCentryx Submits New Drug Application To FDA For Avacopan In ANCA-Associated Vasculitis
Benzinga · 07/09 12:31

所属板块

制药
+0.32%
制药与医学研究
+0.27%

热门股票

代码
价格
涨跌幅

CCXI 简况

ChemoCentryx, Inc.(简称ChemoCentryx)是一家生物制药公司。该公司致力于发现、开发和商业化治疗孤儿与罕见疾病、自身免疫性疾病、炎症性疾病和癌症的口服疗法。该公司针对趋化系统,即包括趋化因子配体及其相关受体的分子网络,以及相关趋化受体从事业务。该公司的候选药物是多种靶向特定趋化因子或趋化受体的小分子,从而阻断由该特定受体驱动的负相关性炎症或抑制性应答,同时保持免疫系统其他部分的完整。该公司的产品包括针对孤儿与罕见疾病、免疫肿瘤学、慢性肾脏疾病和其他炎症与自身免疫性疾病的多个项目。
展开

微牛提供ChemoCentryx Inc(NASDAQ-CCXI)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的CCXI股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易CCXI股票基本功能。